MiMedx Group Inc (MDXG) : 6 analysts are covering MiMedx Group Inc (MDXG) and their average rating on the stock is 1.33, which is read as a Strong Buy. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
MiMedx Group Inc (MDXG) : Currently there are 6 street experts covering MiMedx Group Inc (MDXG) stock. The most bullish and bearish price target for the stock is $13 and $9 respectively for the short term. The average price target of all the analysts comes to $11.5. The estimated standard deviation from the target is $1.38.
For the current week, the company shares have a recommendation consensus of Buy.
MiMedx Group Inc (NASDAQ:MDXG): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $8.50 and $8.06 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $8.60. The buying momentum continued till the end and the stock did not give up its gains. It closed at $8.20, notching a gain of 0.37% for the day. The total traded volume was 1,715,565 . The stock had closed at $8.17 on the previous day.
MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Companys biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant, which is referred as an allograft. MiMedx is the supplier of amniotic tissue, having supplied over 350,000 allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.